EN | UA
EN | UA

Help Support

Back

Fremanezumab: prophylactic treatment for chronic migraine

Fremanezumab: prophylactic treatment for chronic migraine Fremanezumab: prophylactic treatment for chronic migraine
Fremanezumab: prophylactic treatment for chronic migraine Fremanezumab: prophylactic treatment for chronic migraine

What's new?

With long duration of action and long interval between doses, Fremanezumab shows higher clinical efficacy than other treatments used in the prevention of migraine.

With a significant reduction in the number of migraine days, average headache days per month and headache-associated disability, Fremanezumab exhibits considerable outcomes over placebo in 12-week trial. It was a double-blind, randomized, placebo-controlled, phase 3 trial, conducted to assess the efficacy, side-effect and safety profile of two subcutaneous dose treatment of Fremanezumab in preventing chronic migraine.

Selected patients were randomized to receive Fremanezumab quarterly (625 mg medication at baseline and placebo at 4 and 8 week), monthly (625 mg medication at baseline and 225 mg at 4 and 8 week) or matching placebo subcutaneously. Following treatment, Fremanezumab monthly exhibited significant a reduction in headache days per month followed by Fremanezumab quarterly and placebo. Five patients from each Fremanezumab and three from placebo group found with abnormalities in hepatic functionality.  Altogether, Fremanezumab is a potent drug for chronic migraine management, however, further investigation is required to assess associated long-term safety and durability. 

Source:

N Engl J Med. 2017 Nov 30;377(22):2113-2122

Article:

Fremanezumab for the Preventive Treatment of Chronic Migraine

Authors:

Stephen D. Silberstein et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: